Alcobra Ltd


Alcobra Ltd (ADHD) and Transition Therapeutics Inc (TTHI): Two Failed CNS Drug Trials

Two drugs directed at behavioral disorders failed mid-stage studies on Wednesday morning, said sponsors Alcobra Ltd (NASDAQ:ADHD) and Transition Therapeutics Inc (USA) (NASDAQ:TTHI), yet …

Stock Update (NASDAQ:ADHD): Alcobra Ltd Announces Results From Phase 2 Clinical Trial of MDX for Fragile X Syndrome

Alcobra Ltd (NASDAQ:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit …

Stock Update (NASDAQ:ADHD): Alcobra Ltd Announces First Quarter 2015 Financial Results and Provides Corporate Update

Alcobra Ltd (NASDAQ:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit …

Company Update (NASDAQ:ADHD): Alcobra Ltd. to Present at Two CNS Focused Conferences in April

Alcobra Ltd (NASDAQ:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity …

Roth Capital Maintains Buy On Alcobra Ltd Ahead Of Upcoming Phase 3 Initiation

In a research note released today, Roth Capital research team, led by analyst Debjit Chattopadhyay, maintained a Buy rating on Alcobra Ltd (NASDAQ:ADHD) with a $10 price …

Stock Update (NASDAQ:ADHD): Alcobra Ltd. to Present at BIO CEO & Investor Conference

Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit …

ADHD: Alcobra Ltd. Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Over-Allotment Option

Alcobra Ltd. (Nasdaq:ADHD) today reported that it has closed its previously announced public offering of ordinary shares.

ADHD: Alcobra Ltd. Prices Public Offering of Ordinary Shares

Alcobra Ltd. (Nasdaq:ADHD) announced the pricing of its previously announced underwritten public offering of 6,500,000 ordinary shares at an offering price of $4 …

Alcobra: While The Stock Is Under Pressure Our Long-Term Thesis Remains Intact, Says Roth Capital

In a research report sent to investors yesterday, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Alcobra Ltd (NASDAQ:ADHD), but reduced …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts